EN DE
Watch ChoA Pharmaceutical Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ChoA Pharmaceutical Co.Ltd (034940) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of ChoA Pharmaceutical Co.Ltd stock KRW 2,645, price KRW 1,486, upside +78.0%, quality 43 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7034940007

CP ChoA Pharmaceutical Co.Ltd logo Thin data Nov 14, 2026

ChoA Pharmaceutical Co.Ltd

034940 · KQ

Cheap (44% below fair value), but weak company and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value 2,645 KRW · Strongly undervalued 
Low debt 
Even on cautious assumptions the value is 33% above the price (1,974 KRW). 
Quality 43/100 
Mixed vs. peers (4/10) 
Falling price (downtrend) 
Weak Growth (revenue 5y −1.9 %/yr in KRW) 
Loss-making · -4.6% net margin (TTM) 
Negative free cash flow 
Narrow moat 12/100
Thin data 
Watch ChoA Pharmaceutical Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

25,150 KRW 1,478 KRW Fair Value 2,645 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range 1,478 KRW – 25,150 KRW · fair‑value band 1,974 KRW – 3,947 KRW · the 1,486 KRW price screens below the 2,645 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow ChoA Pharmaceutical Co.Ltd in your weekly email

Every Wednesday you see whether ChoA Pharmaceutical Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc.

Show moreShow less

Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral nervous system; gynecologic diseases; antibiotics, antigens, and anthelmintic; and antitumor, as well as other metabolite medicines.

The company offers its products in the form of tablets, capsules, granules, syrups, solutions, drinkable ampoules, and sachets. It also provides medicine supply and pharmacy management services. The company exports its products to approximately 20 countries worldwide.

The company was founded in 1964 and is headquartered in Seoul, South Korea.

Stock analysis

ChoA Pharmaceutical Co.Ltd (034940) currently trades at 1,486 KRW, while our model-based Fair Value estimate is 2,645 KRW, implying the stock looks roughly 44% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the data coverage at low.

Scenario range: 1,974 KRW (bear) to 3,947 KRW (bull), the price of 1,486 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ChoA Pharmaceutical Co.Ltd reported revenue of 59.3B KRW in FY2025 versus 57.6B KRW in FY2021, a compound +0.8%/yr. Reported net income was −6.8B KRW in FY2025.

Key figures

Market cap 10.5B KRW (≈ $7.9M) Micro · P/S ratio 0.17 · EPS (TTM) −453.78 KRW · Net margin −4.6% · Return on equity −11.8% · Return on assets (EBIT) −9.5% (5-year average) · Operating margin −0.2% · Revenue (TTM) 61.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 72% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 78%, 034940 screens cheaper than that median.

Fair Value models

Bear 1,974 KRW Fair Value 2,645 KRW Bull 3,947 KRW
Price 1,486 KRW · Upside +78.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1,974 KRW 2,645 KRW 3,947 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,974 KRW 2,645 KRW 3,947 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Start year 2020 (pandemic). Over 10 years: +1.7% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4.2% (2020) → −11.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 034940, get fair value alerts →

Compare ChoA Pharmaceutical Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside +78.0% · Top 25%
Profitability
Return on assets −10.5% · Bottom 25%
Net margin (12 months) −4.6% · Bottom 25%
Operating margin (12 months) −0.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 11.3% · Above median
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.37× · Cheapest 25%
P/S (12 months) 0.15× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 18
FUTURE (revenue growth)57 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs 034940
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs 034940
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs 034940
Haleon plc HLN $9.17 $8.62 −6% vs 034940
Merck KGaA MRK €149.60 €108.83 −27% vs 034940
Galderma Group GALD CHF 191.40 CHF 111.92 −42% vs 034940
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs 034940
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs 034940
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs 034940
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs 034940

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ChoA Pharmaceutical Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ChoA Pharmaceutical Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/034940

Frequently asked questions

Is ChoA Pharmaceutical Co.Ltd (034940) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of 2,645 KRW versus a price of 1,486 KRW, about +78% upside (undervalued).
What is the fair value of 034940?
Our model-based fair value for ChoA Pharmaceutical Co.Ltd is 2,645 KRW (as of Nov 14, 2026), built from audited fundamentals. The current price: 1,486 KRW.
What is the quality score of 034940?
ChoA Pharmaceutical Co.Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChoA Pharmaceutical Co.Ltd (034940)?
Our model-based price target is the fair value of 2,645 KRW (as of Nov 14, 2026) from 1 valuation models. Cautious scenario 1,974 KRW, optimistic scenario 3,947 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ChoA Pharmaceutical Co.Ltd stock forecast for 2026?
Our models put fair value at 2,645 KRW, about +78% upside versus a price of 1,486 KRW (undervalued). Cautious scenario 1,974 KRW, optimistic scenario 3,947 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ChoA Pharmaceutical Co.Ltd (034940)?
ChoA Pharmaceutical Co.Ltd reported trailing-twelve-month revenue of about 61.2B KRW (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of ChoA Pharmaceutical Co.Ltd (034940)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChoA Pharmaceutical Co.Ltd it is 2,645 KRW per share (as of Nov 14, 2026), against a price of 1,486 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is ChoA Pharmaceutical Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 034940 trades below its calculated fair value: price 1,486 KRW, fair value 2,645 KRW, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 034940?
No. The price is what the market pays today (1,486 KRW); the fair value is what the company's own numbers justify (2,645 KRW). For ChoA Pharmaceutical Co.Ltd the two are 1,159 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ChoA Pharmaceutical Co.Ltd worth?
The market values ChoA Pharmaceutical Co.Ltd at about 10.5B KRW (market capitalisation, as of Nov 14, 2026). Per share that is 1,486 KRW; our models calculate a fair value of 2,645 KRW per share.
What do the bullish and bearish scenarios say about 034940?
Our models span a range for ChoA Pharmaceutical Co.Ltd: cautious scenario 1,974 KRW, base 2,645 KRW, optimistic 3,947 KRW per share (as of Nov 14, 2026, price 1,486 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ChoA Pharmaceutical Co.Ltd (034940)?
Balance-sheet figures for ChoA Pharmaceutical Co.Ltd (as of Nov 14, 2026): return on equity −11.8%, debt of 0.08 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 034940 from its 52-week high?
ChoA Pharmaceutical Co.Ltd trades at 1,486 KRW, about 72% below its 52-week high of 5,320 KRW and 1% above the low of 1,478 KRW (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of 2,645 KRW is for.
Which stocks are comparable to ChoA Pharmaceutical Co.Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChoA Pharmaceutical Co.Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price 1,486 KRW, calculated fair value 2,645 KRW (+78%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 034940 calculated?
We run ChoA Pharmaceutical Co.Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 2,645 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. ChoA Pharmaceutical Co.Ltd currently trades 44% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChoA Pharmaceutical Co.Ltd (034940)?
The closing price on Nov 13, 2026 was 1,486 KRW. Our model-based fair value is 2,645 KRW, about +78% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChoA Pharmaceutical Co.Ltd right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (1,974 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,974 KRW to 3,947 KRW) leaves room in how you read the outcome.

Key figures of ChoA Pharmaceutical Co.Ltd

How large is the market capitalisation of ChoA Pharmaceutical Co.Ltd (034940)?
The market capitalisation of ChoA Pharmaceutical Co.Ltd is 10.5B KRW (≈ $7.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChoA Pharmaceutical Co.Ltd (034940)?
The price-to-sales ratio of ChoA Pharmaceutical Co.Ltd is 0.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ChoA Pharmaceutical Co.Ltd (034940)?
Earnings per share at ChoA Pharmaceutical Co.Ltd are −453.78 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ChoA Pharmaceutical Co.Ltd (034940)?
The net margin of ChoA Pharmaceutical Co.Ltd is −4.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChoA Pharmaceutical Co.Ltd (034940)?
The return on equity (ROE) of ChoA Pharmaceutical Co.Ltd is −11.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChoA Pharmaceutical Co.Ltd (034940)?
On an EBIT basis the return on assets of ChoA Pharmaceutical Co.Ltd is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChoA Pharmaceutical Co.Ltd (034940)?
The operating margin of ChoA Pharmaceutical Co.Ltd is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChoA Pharmaceutical Co.Ltd (034940)?
Revenue at ChoA Pharmaceutical Co.Ltd is growing +11.3% versus a year earlier (3y avg −4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ChoA Pharmaceutical Co.Ltd (034940)?
Earnings per share at ChoA Pharmaceutical Co.Ltd are growing +360% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ChoA Pharmaceutical Co.Ltd (034940) generate?
The free cash flow of ChoA Pharmaceutical Co.Ltd is −5.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ChoA Pharmaceutical Co.Ltd (034940) carry?
The net debt of ChoA Pharmaceutical Co.Ltd is 22.7B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ChoA Pharmaceutical Co.Ltd in the live analysis

One click puts ChoA Pharmaceutical Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.